Literature DB >> 17227691

European Pharmacopoeia foot-and-mouth disease vaccine potency testing in cattle: between test variability and its consequences.

N Goris1, P Merkelbach-Peters, V I Diev, D Verloo, V M Zakharov, H-P Kraft, K De Clercq.   

Abstract

In the event of a foot-and-mouth (FMD) outbreak in a densely populated livestock area within the European Community, emergency vaccination will most likely be employed. The objective of the present study was to support the European FMD control policy by evaluating the between test variability of the European accepted method for assessing the potency, a major determinant in vaccine choice, of an FMD vaccine batch. The test system suffers from low in vivo repeatability and reproducibility (67.6 and 58.8%, respectively). Consequently, the results of 10 identical, individual vaccine potency tests using an FMD virus O1 Manisa vaccine batch indicate that the obtained potency of a vaccine with an overall 50% protective dose (PD(50)) value of 9.99 may vary from 4.59 to 24.25 PD(50).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17227691     DOI: 10.1016/j.vaccine.2006.12.049

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Validation of a PCR-oligochromatography test for detection of Trypanozoon parasites in a multicenter collaborative trial.

Authors:  F Claes; S Deborggraeve; D Verloo; P Mertens; J R Crowther; T Leclipteux; P Büscher
Journal:  J Clin Microbiol       Date:  2007-09-19       Impact factor: 5.948

2.  Interferon-γ induced by in vitro re-stimulation of CD4+ T-cells correlates with in vivo FMD vaccine induced protection of cattle against disease and persistent infection.

Authors:  Yooni Oh; Lucy Fleming; Bob Statham; Pip Hamblin; Paul Barnett; David J Paton; Jong-Hyeon Park; Yi Seok Joo; Satya Parida
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

3.  Efficacy of a high-potency multivalent foot-and-mouth disease virus vaccine in cattle against heterologous challenge with a field virus from the emerging A/ASIA/G-VII lineage.

Authors:  Ryan Waters; Anna B Ludi; Veronica L Fowler; Ginette Wilsden; Clare Browning; Simon Gubbins; Bob Statham; Abdelghani Bin-Tarif; Valerie Mioulet; David J King; Claire Colenutt; Emma Brown; Pascal Hudelet; Donald P King
Journal:  Vaccine       Date:  2018-03-02       Impact factor: 3.641

4.  Large-scale production of foot-and-mouth disease virus (serotype Asia1) VLP vaccine in Escherichia coli and protection potency evaluation in cattle.

Authors:  Yan Xiao; Hong-Ying Chen; Yuzhou Wang; Bo Yin; Chaochao Lv; Xiaobing Mo; He Yan; Yajie Xuan; Yuxin Huang; Wenqiang Pang; Xiangdong Li; Y Adam Yuan; Kegong Tian
Journal:  BMC Biotechnol       Date:  2016-07-02       Impact factor: 2.563

5.  Cross-Protection Induced by a A/MAY/97 Emergency Vaccine Against Intra-Serotype Heterologous Challenge with a Foot-and-Mouth Disease Virus from the A/ASIA/G-VII Lineage.

Authors:  Aldo Dekker; Beatriz Sanz-Bernardo; Nagendrakumar Balasubramanian Singanallur; Anna B Ludi; Jacquelyn Horsington; Phaedra L Eblé; Donald P King; Wilna Vosloo
Journal:  Vaccines (Basel)       Date:  2020-01-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.